Press Releases Dicot AB

Equities

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-06-04 pm EDT			5-day change	1st Jan Change
0.27 ^SEK	-0.55%		+5.26%	-15.09%

May. 06	Dicot AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 06	Dicot AB has Changed its Name to Dicot Pharma AB	CI

Today Dicot AB becomes Dicot Pharma AB	May. 30	AQ
Dicot presents interim report Q1 2024	May. 06	AQ
Good safety and improved erectile function reported from Dicot's phase 1 study	Apr. 23	AQ
Dicot in preparation for clinical phase 2a trial	Apr. 12	AQ
Reporting from Dicot's phase 1 study end of April	Apr. 05	AQ
BioStock: Dicot's phase I study fully recruited	Mar. 14	AQ
Recruitment completed in Dicot's phase 1 trial	Mar. 11	AQ
Dicot's CEO tells BioStock: "Several prominent people want to be part of the journey"	Feb. 29	AQ
Dicot AB Year-End Report 2023	Feb. 26	AQ
BioStock: Good safety profile for Dicot's LIB-01	Jan. 26	AQ
Positive results from the first part of Dicot's phase 1 study	Jan. 23	AQ
Dicot applies for patent covering new manufacturing technology	Jan. 11	AQ
Dicot invited to present at ESSM for the third time	Jan. 05	AQ
BioStock: Interim results from Dicot's phase I study to be released earlier than expected	Dec. 20	AQ
Partial results from Dicot's phase 1 trial to be presented early next year	Dec. 15	AQ
BioStock: Great interest in Dicot's LIB-01	Nov. 30	AQ
Dicot gains significant interest at North America's major sexual medicine congress	Nov. 24	AQ
Dicot's warrants of series TO5 subscribed at 85.4%, provides the company 16.5 MSEK before cost	Nov. 17	AQ
Dicot initiates repeated dosing in its clinical study	Nov. 14	AQ
Letters of intent from major owners, directors, and management to subscribe for SEK 4.7 million (24.2%) in Dicot's TO5 which runs until November 15, 2023	Nov. 02	AQ

No results for this search